You will be given a definition of a task first, then an example. Follow the example to solve a new instance of the task.
Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

"Although the story didn't cite the cost of appendectomy emergency or urgent surgery and we wish it had, we nonetheless will give it a satisfactory score because it at least cited what the editorial writer wrote, ""A secondary benefit is the savings to the hospital generated by minimizing staff and anesthesiologist presence late in the evening and during the wee hours of the morning."" As with our harms score above, although the story didn't give absolute numbers, in this case we think it was sufficient for it to report that ""The scientists found no significant difference among the groups in the patients' condition 30 days after surgery or in the length of their operation or hospital stay."" Although the story didn't give absolute numbers, in this case we think it was sufficient for it to report that ""The scientists found no significant difference among the groups in the patients' condition 30 days after surgery or in the length of their operation or hospital stay."" Despite running less than 300 words, this story did an adequate job in explaining the quality of the evidence, including pointing out limitations. No disease-mongering here. The story meets the bare minimum requirement for this criterion in that it at least cited what an editorial stated. The focus of the story was on a study comparing emergency appendectomy with surgery done up to 12 hours later or beyond. This is the whole focus of the story and one we applaud when it begins: ""Appendectomy is the most common emergency surgery in the world, but it doesn't have to be."" There were no claims made about the novelty of this research, and we may have wished for a bit more context on this. Nonetheless, the potential for guiding future care decisions was made clear. Not applicable. Given that the story only pulled excerpts from the journal article and the accompanying editorial, and didn't include any fresh quotes from interviews, we can't be sure of the extent to which it may have been influenced by a news release."
Solution: Some appendicitis cases may not require 'emergency' surgery
Why? The paragraph mentions that "Appendectomy is the most common emergency surgery in the world, but it doesn't have to be." which is considered evidence for the output. Thus, the output is a valid claim.

New input: "The two drugs work through different mechanisms of action, but there is a synergistic effect that inhibits the growth of prostate cancer cells," said Xi Cheng, assistant research professor at Rutgers, the State University of New Jersey, who conducted the study. His team administered a combination of Celebrex, a non-steroidal anti-inflammatory drug used to treat arthritis and other pain, and Lipitor, a cholesterol lowering statin, to cultured mice tumors in order to measure the transition of early prostate cancer to its more aggressive and potentially fatal stage. Both drugs are sold by Pfizer Inc, but the company played no role in the National Institutes of Health-funded study, Zheng said. The researcher said both drugs have been shown in earlier studies to have some impact on cancer growth when used alone. The Rutgers team found that the combination of low doses of Lipitor and Celebrex had a more potent impact on tumor growth than a higher dose of either agent when used separately. Prostate cancer is the second-leading cause of cancer death in men in the United States, with more than a quarter-million new cases appearing each year, according to the American Cancer Society. In the early stage of the disease, prostate cancer cells depend on androgen hormones, such as testosterone, to grow. Treatment involves either decreasing the production of the hormone or blocking its action. "Anti-androgen therapy slows the prostate cancer but eventually the cancer becomes androgen-independent, the therapy becomes ineffective and the cancer cells become more aggressive," said Zheng. "Treatments available for the later stage cancers are not very good," Allan Conney, director of cancer research at Rutgers, said in a statement. "Oncologists employ classical chemotherapy drugs which are very toxic and don't work all that well." The objective of the Rutgers study was to indefinitely delay the transition to androgen-independence, prolonging the time during which the cancer would be responsive to low-toxicity, anti-hormone therapy. Zheng said it appears that a cell signaling pathway for tumor cell growth is inhibited by the combination of the two compounds. He said human clinical trials are being planned.
Solution:
Celebrex-Lipitor combo may fight prostate cancer.